Thus, the mutational load can only be beneficial for driving an immune response if: 1) tumor cells shed high numbers of neoantigens, 2) neoantigens are phagocytosed by APCs, 3) antigen peptides are processed and loaded onto MHC molecules on the surface of APCs, 4) APCs successfully engage T cells through MHC-TCR interactions, and finally, 5) the presence of co-stimulatory signaling. Here, HLA-C is linked to neoplasm.